Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Mei Pharma Inc
(NQ:
MEIP
)
3.170
-0.010 (-0.31%)
Streaming Delayed Price
Updated: 10:47 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mei Pharma Inc
< Previous
1
2
3
4
5
6
7
Next >
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
August 12, 2024
From
MEI Pharma, Inc.
Via
Business Wire
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 22, 2024
Via
Benzinga
MEI Pharma to Consider Strategic Alternatives
July 22, 2024
From
MEI Pharma, Inc.
Via
Business Wire
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 16, 2024
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
May 14, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
May 09, 2024
MEIP stock results show that MEI Pharma beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
May 09, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
April 11, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
March 26, 2024
From
MEI Pharma, Inc.
Via
Business Wire
5 Value Stocks In The Healthcare Sector
February 19, 2024
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
February 15, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
February 13, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
January 16, 2024
From
MEI Pharma, Inc.
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
January 08, 2024
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
December 14, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
December 11, 2023
From
MEI Pharma, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 16, 2023
Via
Benzinga
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
November 09, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
November 08, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
November 06, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
November 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
November 01, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Recommends Stockholders Not to Consent
October 17, 2023
From
MEI Pharma
Via
Business Wire
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
October 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
September 28, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
September 26, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Earnings Scheduled For September 26, 2023
September 26, 2023
Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.